Trial Profile
An Open-label Non-randomized, Phase 1 Single Dose Study to Evaluate the Pharmacokinetics and Safety of Copanlisib in Subjects With Impaired Hepatic or Renal Function in Comparison to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 19 May 2020 Status changed from active, no longer recruiting to completed.
- 02 Mar 2020 Planned primary completion date changed from 31 Mar 2020 to 13 Mar 2020.